ScreenerHero

CLBIO Corline Biomedical AB

STO · SE · Healthcare · Biotechnology · corline.se
14.85SEK-2.30%Mkt Cap: 37.12M $P/E: —

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on C…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap37.12M USD
Enterprise Value35.31M USD
Revenue (TTM)1.18M USD
Gross Profit595.53K USD
Net Income (TTM)-1.41M USD
Revenue/Share0.49 SEK
Last Price14.85 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)17.08
PEG—
EV/EBITDA-29.99
EV/Revenue29.80
P/S32.07
P/B4.01
EPS (TTM)-0.49
EPS (Forward)0.89
52W Range
13.1512% of range27.20
52W High27.20 SEK
52W Low13.15 SEK
Profitability
Gross Margin81.37%
Oper. Margin-31.49%
EBITDA Margin-99.37%
Profit Margin-192.31%
ROE-15.69%
ROA-14.93%
Growth
Revenue Growth114.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.69M USD
CapEx (TTM)94.03K USD
FCF Margin-125.58%
FCF Yield-4.01%
Net Debt-2.69M USD
Net Debt/EBITDA2.28
Balance Sheet
Debt/Equity4.97
Current Ratio6.49
Quick Ratio6.12
Book Value/Sh3.79 SEK
Cash/Share1.26 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)24.50 SEK
Upside (mean)+65.0%
Target Range24.50 SEK – 24.50 SEK
# Analysts1
Ownership
Shares Out.26.13M
Float11.30M
Insiders62.42%
Institutions12.84%
Technical
SMA 5016.43 (-9.6%)
SMA 20016.77 (-11.4%)
Beta0.29
S&P 52W Chg14.58%
Avg Vol (30d)11.39K
Avg Vol (10d)7.11K
Technical Indicators
RSI (14)49.4
MACD-0.5470
MACD Signal-0.6611
MACD Hist.+0.1140
BB Upper16.27 SEK
BB Middle14.88 SEK
BB Lower13.48 SEK
BB Width18.75%
ATR (14)0.9827 SEK
Vol Ratio (20d)0.64x